The novel compound 7-[4'-(2-nitroimidazol-l-yl)-butyl]-theophylline (NITP) can be used as an immunologically detectable probe for hypoxic cells. Because of the limited water solubility of NITP, it has been administered dissolved in peanut oil with 10% dimethylsulphoxide (DMSO). A new aqueous formulation has been devised, based on a 50% solution of a modified P-cyclodextrin (Molecusol HPB), which increases the water solubility of NITP 10-fold. The To circumvent this problem, NITP has been administered in vivo as a solution in peanut oil + 10% DMSO . While this formulation has given satisfactory results in the tumour models used, it is clearly unsuitable for clinical administration, and an aqueous preparation of the drug would be preferable.
The presence of poorly oxygenated cells in tumours is thought to be one of the causes of radioresistance in cancer radiotherapy (Gray et al., 1953) , and measurements of tumour oxygenation have been shown to predict the response of tumours to radiotherapy (Bush et al., 1978; Gatenby et al., 1988; Overgaard, 1992) . Tumour hypoxia has also been shown to influence the efficacy of many chemotherapeutic agents. In particular, bioreductive drugs are specifically activated in hypoxic cells and can target those cells that are resistant to radiotherapy (for review see Stratford, 1992) .
Numerous methods have been proposed for measuring tumour hypoxia (for review see Hodgkiss and Wardman, 1992) , in the hope that this would allow treatment to be optimised for individual patients on the basis of the oxygen status of their tumours. In particular, the hypoxia-specific binding of isotopically labelled 2-nitroimidazoles has been used to identify hypoxic cells in tumours, (e.g. Chapman et al., 1982; Franko and Chapman, 1982; Garrecht and Chapman, 1983; Raleigh et al., 1985; Rasey et al., 1985; Urtasun et al., 1986) . Immunological detection of 2-nitroimidazoles has been described (Raleigh et al., 1987; Hodgkiss et al., 1991; Lord et al., 1993) and avoids the administration of radioactive labels, which would be particularly desirable for clinical measurement of tumour hypoxia.
The novel compound 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP), has been described as an immunologically detectable bioreductive probe for hypoxic cells , and appears to offer promise as a method of quantifying tumour hypoxia in vivo. However, the water solubility of NITP is only c. 2 x 10-3 M at 20'C and its administration in vivo, dissolved in water or saline, would require an inconveniently large volume of drug solution to be given to achieve an adequate dose level of c. 0.45 lsmol g-'.
To circumvent this problem, NITP has been administered in vivo as a solution in peanut oil + 10% DMSO . While this formulation has given satisfactory results in the tumour models used, it is clearly unsuitable for clinical administration, and an aqueous preparation of the drug would be preferable.
,-Cyclodextrin consists of seven glucose units joined into a ring, taking up the shape of a three-dimensional torus with a hydrophobic cavity. 'Guest' molecules of a suitable size can fit into the central cavity, and the inclusion complex thus formed can increase the aqueous solubility of lipophilic compounds (Szejtli, 1982) . Although P-cyclodextrin is not very water-soluble, chemically modified derivatives are available with greatly increased water solubility. This paper describes the use of a modified 2-hydroxy-propyl-p-cyclodextrin (Molecusol 
Chemicals
The novel compound 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) was custom synthesised by Lancaster Synthesis using similar methods to those previously described . 2-Hydroxypropyl-,-cyclodextrin (Molecusol HPB) was obtained from Bioquote. Dimethyl sulphoxide (DMSO) and other reagents were BDH AnalaR grade.
In vivo studies (a) Tumours The carcinoma CaNT used in this study is a poorly differentiated mammary carcinoma of spontaneous origin, which is maintained by serial passage in CBA mice. The CaNT tumour has a volume doubling time of less than 3 days. Tumours were implanted in the dorsal subcutaneous site and were used at a mean diameter of 10 mm calculated from three orthogonal measurements. These studies were performed under the regulations stipulated by the Animals (Scientific Procedures) Act (1986).
(b) Drug administration The hypoxia probe NITP, was administered at various doses by the oral, i.p., i.v. and i.t. routes. A number of vehicles were employed: peanut oil + 10% DMSO, 0.44 M Molecusol, or saline. For the peanut oil + 10% DMSO, the drug was dissolved at 4 x 10-2 M, and administered i.p. at either 0.45 or 0.09 ytmol g-' (0.01 1, 0.0022 ml g-' respectively). Solutions of Molecusol HPB (0.44 M) (Molecusol) were prepared and NITP dissolved at 2 x 10-2 M in the solution of Molecusol by heating at 50°C. The solution of NITP in Molecusol was administered at room temperature, orally or i.p. at 0.9 (oral only), 0.45 or 0.09 ttmol g' (0.044, 0.022, 0.0044 ml g' respectively). Intravenous and i.p. administrations were also made using a 2 x 1O-M solution in saline at doses of 0.015 and 0.005 ytmol g-' (i.v. only) (0.0075, 0.0025 ml g-l respectively). The same vehicle was used for i.t. administration, when a total volume of 0.1 ml (c. 0.006 ytmol g-') was given. Following administration of the drug, animals were air breathing and unrestrained, with a normal supply of food and water.
(c) Tissue preparation and analysis Animals were sacrificed by decapitation, a blood sample collected in heparinised tubes and plasma separated by centrifugation. Tumours were excised and divided into two portions, for pharmacokinetic measurements and flow cytometry. In some experiments, samples of liver were also taken for analysis. Plasma and tissue concentrations of NITP were determined by HPLC as previously described , except that a 26% acetonitrile-water solvent mixture was used to improve separation of the metabolite peaks. Half-lives were calculated by linear least-squares regression of logarithmically transformed plasma concentrations. Areas under the curves (AUCs) were derived by the trapezium rule.
The method of preparing fixed single cell suspensions in 70% ethanol from tumours, immmunohistochemically detecting bound adducts of NITP in the cells and quantifying them by flow cytometry has also been described Table I . Where levels of NITP were measured in liver they were similar to those observed in tumours ( Figure 4a ). Higher levels of metabolites, particularly metabolite 2, were found in liver than in the plasma, indicating that liver metabolism was responsible for the production of these metabolites ( Figure  4a and b). As these metabolites are diffusible and distributed throughout the body by the plasma, they are unlikely to be responsible for the localised binding of metabolites of NITP that is observed in the hypoxic regions of tumours.
Use of peanut oil + 10% DMSO as a vehicle for i.p. administration of NITP has been described previously Figure 3a ). This 'slow release' effect probably reflects slow uptake of NITP from a non-aqueous phase, and the subse- Delivery of drugs by i.v. injection can be regarded as nearly instantaneous, thus eliminating the phase of drug uptake. Following i.v. or i.p. injection, the plasma half-life of NITP can be seen to be relatively short. The value quoted for 0.015 Itmol g-in Table I is a linear fit to the terminal elimination phase consistent with the other data in the table. Non-linear regression gave a biphasic curve with a short distribution phase with a half-life of 1.7 min, and an elimination half-life of 9.2 min, similar to that shown in Table I . The volume of distribution using these data was 0.63 ml g I+ 0.05 ml g' I (s.e.m.). Intraperitoneal administration also resulted in rapid uptake and elimination. Direct injection of 2 x 10-3 M NITP into tumours was also carried out in an attempt to administer the drug locally while reducing the overall whole-body exposure. Single injections of 0.1 ml into tumours of c. 10 mm mean diameter gave local tumour concentrations of 1 X 10-0M, averaged over the tumour, with plasma concentrations at least a factor of 20 below this level (Figure 8b ). Plasma clearance was relatively rapid and similar to that obtained following i.v. injection, while clearance from the tumour appeared to be somewhat slower.
There was little binding of NITP in tumours after i.v. injection of a 2 x 10-3 M solution of the drug, probably reflecting the small quantity of drug that could be adminitwo experiments, assessed by fluorescent immunochemical staining and flow cytometry. Points represent means and standard errors from three replicate animals. stered. However, direct injection of a 2 x 10-' M solution of NITP into tumours led to substantial binding. The distribution of NITP in frozen section of such tumours, compared with those obtained following systemic administration (Figure 9a and b) , suggests that much of the metabolic binding reflected either very high local drug concentrations at the site of injection, or hypoxia induced locally. Uneven binding was also observed following injection of 0.033 ml into each of three sites on the tumour with 5 min between each injection.
Discussion
As observed previously , complete absorption of NITP from the peritoneal cavity using peanut oil + 10% DMSO was relatively slow, probably due to the low solubility of the compound in the vehicle in the aqueous environment of the peritoneum. This would give a reservoir exhibiting zero-order absorption kinetics and lead to the slow clearance seen (Table I ). The other routes of administration resulted in much less evidence of delayed absorption (Figures  4-8) , with the exception of the high-dose i.p. Molecusol, when the toxicity of the vehicle, which caused a rapid drop in body temperature, may have resulted in reduced blood flow.
The elimination half-life was also extended for this dose, and the cooling may also have been responsible for the very large plasma AUC, which was more than an order of magnitude greater than for the lower dose administered by the same route. The short half-life seen at the low aqueous doses may reflect some saturation of an elimination mechanism at higher plasma concentrations, although apparent slower clearance may also result from continued absorption of drug from the other vehicles. and therefore reflects the amount of hypoxia in tumours. Some variation is expected in the amount of hypoxia in individual tumours, and a proportion of the variability in the amount of NITP bound in each tumour presumably reflects inter-tumour differences in hypoxic cell fraction. However, variability has also been observed in the time course Figure 3 . bPooled data for three experiments. (Table I) and slow metabolic binding in tumours. When the dose of the aqueous formulation was reduced by a factor of 5, there was no toxicity and the rate of drug binding in tumours was faster.
Oral administration of NITP (0.45 pLmol g-') in Molecusol led to rapid binding of the drug in tumours, despite the pharmacokinetic data suggesting relatively poor exposure of the tumour to the drug, indicated by the low AUC (Table I) . Binding was also observed following a reduction in the dose of NITP to 0.09 limol g-'. While there appeared to be fewer cells containing bound metabolites in tumours left for 2-4 h after drug administration in the first experiment, there appeared to be much less reduction in bound drug over the same time period in the second experiment. The first data set may simply reflect an unfortunate distribution of hypoxic fractions within this group of tumours, as bound metabolites also appear to have been relatively stable over this time period in other groups of tumours. Much of the immunologically identifiable signal is associated with DNA. Cellular RNA is routinely digested from samples for flow cytometry to improve the DNA profiles, and preparation of cell nuclei from fixed whole cells causes little loss of signal. It is possible that some apparent early loss in hypoxic fraction reflects repair of bulky NITP adducts from DNA or turnover of proteins. Some turnover and loss of cells may alsg be occurring after they have bound NITP as kinetic studies show that this tumour has a high cell-loss factor. Following systemic administration of NITP, metabolic binding is observed around the edges of the tumour cords, at a distance of 6-8 cell diameters from the central blood vessels (Figure 9a, Hodgkiss et al., 1991) . Direct i.t. administration of NITP would not appear to be a practical alternative route because drug binding appears to be localised to the injection site (Figure 9b ) and is probably an artifact induced by this method of administering the drug. However, the proportions of cells binding NITP averaged over the tumour were similar to those observed after administration of NITP by other routes. This illustrates how the distribution of bound drug can be more informative than the average amount of drug binding in tumours.
Taken together, these data suggest that it may be possible to use lower doses of NITP to diagnose tumour hypoxia than had previously been thought possible. Both aqueous formulation of NITP and oral administration of the aqueous preparation are feasible and have been demonstrated to be compatible with observation of bioreductive binding of the compound in hypoxic cells in tumours. This suggests that detection of bound NITP could be feasible in clinical studies with oral administration of the drug.
